Initiation, adherence to AIs low for older women with DCIS

(HealthDay)—For older women with estrogen receptor (ER)-positive ductal carcinoma in situ (DCIS), initiation of aromatase inhibitors (AIs) and adherence to treatment are low, according to a study published online Oct. 25 in Cancer.

Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer - Data Points Publication Series - NCBI Bookshelf

Cancers, Free Full-Text

Treatment coverage according to medication, age, and duration of treatment

Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial - ScienceDirect

Frontiers Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer

Impact of Endocrine Therapy Adherence on Outcomes in Elderly Women with Early-Stage Breast Cancer Undergoing Lumpectomy Without Radiotherapy

Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer - Data Points Publication Series - NCBI Bookshelf

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II - ScienceDirect

Nainan Hei - Providence

Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ - Zhao - 2017 - Cancer - Wiley Online Library

Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study. - Abstract - Europe PMC

JBC :: Journal of Breast Cancer

Adjuvant Hormonal Therapy Adherence in Breast Cancer - BCTT

PDF) Tamoxifen Initiation After Ductal Carcinoma In Situ

Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Early Stage Hormone Receptor Positive Breast Cancer - ScienceDirect